New hope for advanced cancer patients: early trial of HRS-6209
NCT ID NCT05781048
First seen Mar 15, 2026 · Last updated Jun 11, 2026 · Updated 14 times
Summary
This early-phase study tests a new drug called HRS-6209 in 56 people with advanced solid tumors who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. This is a first step to see if the drug might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center-
Shanghai, Shanghai Municipality, 201321, China
Conditions
Explore the condition pages connected to this study.